BackgroundCheck.run
Search For

Thomas Paul Bobinski, 51San Diego, CA

Known as:
Thomas P Bobinski Tom P Bobinski

Thomas Bobinski Phones & Addresses

San Diego, CA   

Lafayette, IN   

Tonawanda, NY   

1020 Kenmore Ave, Buffalo, NY 14216    716-8773343   

W Lafayette, IN   

Social networks

Thomas Paul Bobinski

Linkedin

Work

Company: Mirati therapeutics Feb 2017 to Nov 2019 Position: Principal scientist, medicinal chemistry

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Purdue University 2007 to 2013 Specialities: Philosophy

Skills

Chemistry • Organic Chemistry • Analytical Chemistry • Drug Discovery • Organic Synthesis • Nmr • Chromatography • Hplc • Nuclear Magnetic Resonance • Laboratory Skills • Uv/Vis • Medicinal Chemistry • Purification • Mass Spectrometry • Science • Spectroscopy • Laboratory • Research • Synthetic Organic Chemistry • Column Chromatography • Catalysis • Organometallic Chemistry • Lc Ms • Uv/Vis Spectroscopy • Total Synthesis • Organocatalysis • Ftir • Characterization • Gc Ms • Biotechnology • High Performance Liquid Chromatography • Drug Design • Life Sciences • Ir • Research and Development • Pharmaceutical Industry • Standard Operating Procedure • Drug Development • Gas Chromatography • Gmp

Industries

Biotechnology
Get Report
Control this profile

Mentions for Thomas Paul Bobinski

Thomas Bobinski resumes & CV records

Resumes

Thomas Bobinski Photo 17

Postdoctoral Research Associate

Location:
San Diego, CA
Industry:
Biotechnology
Work:
Mirati Therapeutics Feb 2017 - Nov 2019
Principal Scientist, Medicinal Chemistry Ignyta, Inc. Nov 2015 - Jun 2016
Research Scientist Purdue University Dec 2013 - Jun 2015
Postdoctoral Research Associate, Negishi Research Group Negishi Research Group Dec 2013 - Jun 2015
Postdoctoral Research Associate Purdue University 2007 - 2013
Phd Candidate Starks Associates 2004 - 2007
Reasearch Associate
Education:
Purdue University 2007 - 2013
Doctorates, Doctor of Philosophy, Philosophy University at Buffalo 1997 - 2003
Master of Science, Masters, Bachelors, Bachelor of Science, Chemistry
Skills:
Chemistry, Organic Chemistry, Analytical Chemistry, Drug Discovery, Organic Synthesis, Nmr, Chromatography, Hplc, Nuclear Magnetic Resonance, Laboratory Skills, Uv/Vis, Medicinal Chemistry, Purification, Mass Spectrometry, Science, Spectroscopy, Laboratory, Research, Synthetic Organic Chemistry, Column Chromatography, Catalysis, Organometallic Chemistry, Lc Ms, Uv/Vis Spectroscopy, Total Synthesis, Organocatalysis, Ftir, Characterization, Gc Ms, Biotechnology, High Performance Liquid Chromatography, Drug Design, Life Sciences, Ir, Research and Development, Pharmaceutical Industry, Standard Operating Procedure, Drug Development, Gas Chromatography, Gmp

Publications & IP owners

Us Patents

Prc2 Inhibitors

US Patent:
2021003, Feb 4, 2021
Filed:
Jan 29, 2019
Appl. No.:
16/966708
Inventors:
- San Diego CA, US
Matthew Randolph Lee - Del Mar CA, US
Thomas P. Bobinski - San Diego CA, US
Aaron Craig Burns - San Diego CA, US
Nidhi Arora - San Diego CA, US
James Gail Christensen - San Diego CA, US
John Michael Ketcham - San Diego CA, US
International Classification:
C07D 487/04
Abstract:
The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Rock Kinase Inhibitors

US Patent:
2020026, Aug 20, 2020
Filed:
May 5, 2020
Appl. No.:
16/867162
Inventors:
- Malvern PA, US
Thomas P. Bobinski - San Diego CA, US
International Classification:
C07D 498/08
C07D 401/12
C07D 403/12
C07D 471/04
C07D 405/14
Abstract:
The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.

Ezh2 Inhibitors

US Patent:
2018026, Sep 20, 2018
Filed:
Mar 14, 2018
Appl. No.:
15/921097
Inventors:
- San Diego CA, US
Matthew Randolph Lee - Del Mar CA, US
Robert Anthony Galemmo - San Francisco CA, US
Thomas P. Bobinski - San Diego CA, US
International Classification:
C07D 491/048
C07D 519/00
C07D 471/04
C07D 495/04
C07D 498/04
C07D 513/04
A61P 35/00
Abstract:
The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Possible Relatives

Edward J Bobinski  John A Bobinski  Melissa A Bobinski  Michael D Bobinski  Peter P Bobinski  Philip L Bobinski  Amy R Bobinski  Thomas D Johnson  Thomas Stamps  Thomas W Stancil 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.